Iovance Biotherapeutics, Inc. (IOVA) company profile
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
About Iovance Biotherapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Iovance Biotherapeutics is a commercial-stage biotechnology company that develops and delivers individualized tumor-infiltrating lymphocyte cell therapies for patients with solid tumor cancers. Its primary commercial offerings are Amtagvi, a one-time T-cell therapy for adults with advanced melanoma who have undergone prior treatments, and Proleukin, an injectable interleukin-2 medication utilized in cancer treatment regimens and cellular manufacturing. The company distributes its therapies and pharmaceutical products to specialized authorized treatment centers, healthcare professionals, commercial medicine distributors, and biomedical research institutions treating adult oncology patients.
The organization operates a centralized manufacturing site, the Iovance Cell Therapy Center, situated in Philadelphia, Pennsylvania, which possesses an annual production capacity exceeding five thousand patient treatments. To date, treatments manufactured through these proprietary processes have served more than fifteen hundred patients. Geographically, the business delivers cellular therapies across North America, Europe, and the Asia-Pacific region. Its lead product holds regulatory clearance in the United States and Canada, while its secondary product is approved domestically and licensed across multiple international markets.
Summary of the business section of Iovance Biotherapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Iovance Biotherapeutics, Inc.
- Founded
- 2007
- Headquarters
- San Carlos, CA
- Address
- 825 Industrial Road, 4th Floor 94070
- Phone
- (650) 260-7120
- Website
- www.iovance.com
- Employees
- 975, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- IOVA
- Former tickers
- LBIO until Aug 3, 2017
- Exchange
- Nasdaq
- Shares outstanding
- 453M, Jul 29, 2026
- Public float
- $534.80M, Jun 30, 2025
- Filer category
- Accelerated filer
- Stock splits
- 1-for-100 reverse, Sep 26, 2013
- SEC CIK
- 1425205
- CUSIP
- 462260100
- ISIN
- US4622601007
- FIGI
- BBG000FTLBV7
- Share class FIGI
- BBG001T2PM32
- LEI
- 2549002L8WT2ACU5Q878
- EIN
- 75-3254381
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Frederick G. Vogt | Interim CEO & General Counsel, Director | 604,144 |
| Daniel Gordon Kirby | Chief Commercial Officer | 160,576 |
| Corleen M. Roche | Chief Financial Officer | 35,946 |
| Noah Berkowitz | Chief Medical Officer | – |
| Raj K. Puri | Chief Regulatory Officer | 260,842 |
| Igor Bilinsky | Chief Operating Officer | 142,074 |
| Finckenstein Friedrich Graf | Chief Medical Officer | 144,087 |
| Matthew W. Rosinack | SVP, Finance (Int. PFO & PAO) | 89,129 |
| Jean-Marc Bellemin | Chief Financial Officer | 64,993 |
| Michael Weiser | Director | 133,303 |
| Iain D. Dukes | Director | 54,000 |
| Ryan D. Maynard | Director | 57,500 |
| Athena Countouriotis | Director | – |
| Wendy L. Yarno | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.89M | -$1.62M | $1.29M | $6 | $125 |
| FY2024 | $10.95M | $7.05M | $3.26M | $27 | $118 |
| FY2023 | $4.79M | $5.22M | $1.69M | $29 | $119 |
| FY2022 | $5.26M | -$173.21K | $2.16M | $23 | $114 |
| FY2021 Frederick GVogt | $3.22M | $3.17M | $3.27M | $69 | $126 |
| FY2021 Maria Fardis | $7.01M | -$2.48M | $3.27M | $69 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Frederick G. Vogt Interim Chief Executive Officer and President, General Counsel | $800.00K | – | $759.38K | – | $312.00K | $16.80K | $1.89M | -83% |
| Corleen Roche Chief Financial Officer | $243.29K | $50.00K | $387.00K | $574.83K | $194.40K | $6.46K | $1.46M | – |
| Daniel Kirby Chief Commercial Officer | $507.53K | $100.00K | $1.22M | $133.76K | $184.68K | $11.82K | $2.16M | – |
| Raj K. Puri Chief Regulatory Officer | $671.94K | – | $474.62K | – | $181.42K | $13.80K | $1.34M | -58% |
| Igor Bilinsky Chief Operating Officer | $570.53K | – | $379.69K | – | $154.04K | $13.80K | $1.12M | -66% |
| Jean-Marc Bellemin Former Chief Financial Officer | $277.45K | – | $379.69K | – | – | $5.96K | $663.10K | -80% |
| Matthew W. Rosinack Interim Principal Financial Officer and Principal Accounting Officer | $433.51K | $18.75K | $239.19K | – | $91.04K | – | $782.49K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 975 employees, 775 of whom were engaged in research and development, and commercial manufacturing activities, and 200 of whom were engaged in general and administrative support activities.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?